Chronic lymphocytic leukaemia: Transition to a new era
Chronic lymphocytic leukaemia: Transition to a new era
Multi-target S-DNA increases colorectal cancer screening among previously non-compliant patients
p62: Metabolism and the tumour microenvironment
Cancer cells plasticity and drug resistance
Editor's Choice for April 2016
Drugging “undruggable” transcription factor drivers in cancer
Pembrolizumab yielded durable responses in patients with advanced Merkel cell carcinoma
Combination therapy before surgery improves outcomes for patients with HER2 positive breast cancer
Elucidation and pharmacological targeting of tumour checkpoint dependencies
AML17 Trial results: maximum dosage of daunorubicin in AML
Germ line predisposition to leukaemia
Frontline therapy in young patients with myeloma